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regurgitation
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Background:
 
 Left atrial (LA) enlargement is a consequence of organic
mitral regurgitation (MR) but its association with clinical outcome indepen-
dently of MR severity is uncertain.
 
Objectives: 
 
To assess the link between LA volume at diagnosis and out-
come of patients with MR.
 
Methods: 
 
We prospectively enrolled 492 patients (63±15 years, 60%
males) in sinus rhythm with organic MR (RVol. 68±42 mL/beat) and per-
formed triple echocardiographic quantitation (MR severity, LA volume and
left ventricular characteristics). Outcome with medical and surgical manage-
ment were analyzed.  
 
Results:
 
 LA volume indexed to body surface area (LA-index) was 55±26
mL/m
 
2
 
 (<40 ml/m
 
2
 
 in 158, 40-59 ml/m
 
2
 
 in 160 and 60 ml/m
 
2
 
 in 174 patients).
Under medical management, 5-year survival was 80±2.9% and cardiac events
28±3%. Adjusting for established predictors of outcome, LA-index was inde-
pendently associated with survival after diagnosis (HR1.3[1.1-1.5] per 10 ml/
m
 
2
 
 increment, P=0.001). Patients with LA-index 60 mL/m
 
2
 
 had lower 5-year
survival than those with no or mild LA enlargement (P<0.0001) and than sur-
vival expected in US population (53±8.6% versus 76%, P=0.017). Compared
to patients with LA-index <40 ml/m
 
2
 
, those with LA-index 60 mL/m
 
2
 
 had
increased mortality (HR2.8[1.2-6.5], P=0.016) and cardiac events (HR5.2[2.6-
10.9], P<0.0001) with medical management. Mitral surgery was associated
with decreased mortality (HR 0.46[0.26-0.84], P=0.01) and cardiac events (HR
0.38[0.23-0.62] P=0.0001). After surgery patients with LA-index 60 mL/m
 
2
 
did not incur excess mortality or cardiac events (P>0.30). 
 
Conclusion:
 
 In organic MR, LA-index at diagnosis predicts long-term out-
come, incrementally to known predictors of outcome. This marker of risk is
particularly important because mitral surgery in these patients markedly
improves outcome and restores life-expectancy. LA-index should be measured
in routine clinical practice for risk-stratification and for clinical decision
making in patients with organic MR.
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Brain natriuretic peptide predicts left ventricular contractile reserve
in asymptomatic degenerative mitral regurgitation
 
Julien Magne, Kim O’Connor, Marie Moonen, Patrizio Lancellotti, Luc A.
Piérard
 
CHU Sart Tilman, Cardiologie, Liège, Belgique
 
Background:
 
 Current guidelines recommend mitral surgery in asymptom-
atic patients with severe degenerative mitral regurgitation (DMR) even when
left ventricular (LV) systolic function is preserved. LV longitudinal deforma-
tion, quantified with 2D speckle tracking analysis (2DSt), can detect LV con-
tractile reserve (CR). Moreover, plasma brain natriuretic peptide (BNP) may
be used for risk stratification in patients with DMR. We sought to assess
whether BNP may be used to identify LVCR in asymptomatic DMR.
 
Methods and results:
 
 Resting and exercise transthoracic echocardiography
was performed in 82 consecutive asymptomatic patients with moderate to
severe DMR and with preserved LV systolic function. The presence of LVCR
was defined as an exercise-induced changes in global longitudinal strain
(GLS) >2%. Simultaneously to resting echocardiography, plasma BNP level
was measured. GLS increased during exercise (from 20.9±3.1 to 23.4±3.4%,
p<0.001) and CR was found in 45 patients (56%). Patients with CR were sig-
nificantly younger (p=0.025) and had lower LV filling pressure (p=0.04) than
to those without CR. BNP was significantly higher in patients without CR
(42.7±2 vs.14.8±2pg/ml, p<0.0001) and there was a good correlation between
BNP and exercise-induced changes in GLS (r=-0.77, p<0.001). On multivari-
able analysis, BNP was independently associated with exercise-induced
changes in GLS (p<0.001). ROC curves showed that BNP>26pg/ml predicted
the absence of CR with good accuracy (sensitivity: 92%; specificity: 93%).
Moreover, multivariable regression revealed that, after adjustment for age, sex,
E/Ea ratio and resting GLS, only BNP was independently associated with CR
(OR=1.4, 95%CI: 1.2-2, p<0.001). 
 
Conclusion:
 
 In asymptomatic DMR and normal LV systolic function, CR
may be absent in a large proportion of patients (45%). BNP is highly accurate
to identify patients with subclinical LV dysfunction and no CR. Consequently,
BNP could routinely be used to improve risk stratification. 
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Exercise pulmonary hypertension in asymptomatic organic mitral
regurgitation
Julien Magne, Kim O’Connor, Marie Moonen, Patrizio Lancellotti, Luc A.
Piérard
CHU Sart Tilman, Cardiologie, Liège, Belgique
Background:
 
 Current guidelines recommend mitral valve surgery for
asymptomatic patients with severe organic mitral regurgitation (OMR) and
preserved left ventricular systolic function when exercise pulmonary hyperten-
sion (PHT) is present. The aim of this study was to identify the determinants
of exercise PHT and the impact on symptom-free survival.
 
Methods and results:
 
 Comprehensive resting and exercise transthoracic
echocardiography were performed in 78 consecutive asymptomatic patients
(61±13 years, 56% males) with  moderate OMR. Resting and exercise PHT
were defined as a systolic pulmonary arterial pressure (SPAP) >50mmHg and
>60mmHg, respectively. Exercise PHT was more frequent than resting PHT
(48% vs. 15%, p<0.001). In multivariable analysis, exercise ERO was an inde-
pendent determinant of exercise SPAP (p<0.0001) and exercise PHT
(p=0.002). During follow-up (mean: 19±14 months), 40 patients (51%)
remained asymptomatic whereas 38 (49%) developed symptoms. Symptom-
free survival was 71±5%, 54±6% and 40±7% at 1, 2- and 3-year, respectively.
Resting PHT and exercise PHT were associated with markedly reduced 2-year
symptom-free survival (36±14% vs. 59±7%, p=0.04; 35±8% vs. 75±7%,
p<0.0001). After adjustment for age and sex, the impact of resting PHT on
symptoms was no longer significant. Multivariable Cox model identified exer-
cise PHT as an independent predictor of the occurrence of symptoms (Hazard-
ratio=2.8, 95%CI: 1.4-5.4, p=0.002). ROC curves revealed that exercise SPAP
was more accurate than SPAP to predict the occurrence of symptoms during
follow-up (p=0.032). SPAP> 56mmHg predicted symptoms with good speci-
ficity (73%) and sensitivity (82%).   
 
Conclusions:
 
 Exercise PHT is frequent in patients with asymptomatic OMR.
Exercise MR severity is a strong independent predictor of both exercise SPAP and
exercise PHT. Exercise PHT is associated with markedly low 2-year symptom-free
survival emphasizing the use of exercise stress echocardiography. 
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Purpose:
 
 The impact of transcatheter aortic valve implantation (TAVI) on
mitral regurgitation (MR) is controversial. Two recent publications have
reported improvement in MR grades following implantation of the Edwards-
SAPIEN endoprosthesis. These findings were not replicated with the Core-
Valve. The time course of improvement in MR grades with the Edwards-
SAPIEN valve has not been described on an individual patient basis and the
potential mechanisms of benefit are unclear. The aim of this study was to
assess the acute and intermediate changes in MR severity after TAVI with the
Edwards-SAPIEN endoprosthesis 
 
Methods:
 
 Echocardiography was performed in 22 consecutive patients
before and after treatment, and at 1 month follow-up. MR was assessed by
color flow mapping and was graded as none, mild, moderate, or severe. MR
was defined as organic or functional.
 
Results:
 
 The aortic valve area increased from pretreatment 0.72 cm2 to
post-treatment 1.87 cm2 and postdischarge 1.81 cm2 (P<0.0001). Before inter-
vention MR was present in 73% of the patients. It was mild, moderate, or
severe in 36% (n=8), 32% (n=7), and 4% (n=1) respectively. MR was defined
as organic in 6 patients (27%) and functional in 10 patients (45%). Compared
to baseline, MR grades improved by 1 month (p for trend=0.01). This benefit
was secondary to a reduction in regurgitation grades in 50% of patients with
an MR at baseline (n=6), while no worsening was observed in the other
patients with an MR (n=6) and no occurrence of MR was observed in patients
without MR (n=6). A trend for a greater improvement in MR grade was
observed in patients with functional MR (n=7, - 1.00) compared to those with
an organic MR (n=5, - 0.294; p=0.10).
 
Conclusion:
 
 In consecutive patients with a successful implantation of an
Edwards-SAPIEN valve a significant improvement in MR was observed. This
benefit was secondary to an improvement in 50% of patients with an MR and
no worsening in the others. 
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Assessment of thromboembolic risk in mitral stenosis. Is left atrial
volume superior to diameter? 
Niall Keenan, Caroline Cueff, Claire Cimadevilla, Eric Brochet, Laurent
Lepage, Delphine Detaint, Bernard Iung, Alec Vahanian, David Messika-
Zeitoun
CHU Bichat, Cardiologie, Paris, France
Objective: 
 
In patients with mitral stenosis (MS) in sinus rhythm (SR)
without thromboembolic complications, current guidelines recommend antico-
agulation if the left atrium (LA) is enlarged based on M-mode diameter. How-
ever, LA diameter poorly reflects LA enlargement. The aim of this study was
to compare the predictive value of LA diameter and volume for the risk of
embolic events as assessed by LA appendage emptying velocity (LAAv)
<25cm/s and dense LA spontaneous contrast (SEC) during transesophageal
echocardiography (TEE).
 
Methods: 
 
152 patients (53±14years,73% female) with severe MS (valve
area <1.5cm
 
2
 
) were prospectively enrolled. A subset of 80 patients were iden-
tified in SR who also underwent clinically indicated TEE.
 
Results: 
 
Mean LA diameter and LA volume were significantly correlated
(50±7[32-77]mm vs. 152±70[67-720]ml,(r=0.71,p<0.001) but the relation was
curvilinear and the 95% CI increased with LA diameter. In the SR/TEE subset,
LA diameter was not significantly different between patients with normal vs.
low LAAv (50±6 vs. 48±6mm,p=0.13) or between those with dense SEC vs.
no/mild SEC (49±6 vs. 46±5mm,p=0.11). In contrast body surface area
(BSA)-indexed LA volume differentiated patients with normal vs. low LAAv
(86±17 vs. 71±17 ml/m
 
2
 
,p<0.01) and patients with dense SEC vs. no/mild
SEC (81±16 vs. 63±15 ml/m
 
2
 
, p<0.01). BSA-indexed LA volume provided the
highest area under the curve (AUC)(0.85) for high thromboembolic risk and
LA diameter the lowest (0.65). A BSA-indexed LA volume above 60 ml/m
 
2
 
provided an excellent 90% sensitivity despite 44% specificity, 76% positive
predictive value and 70% negative predictive value.
 
Conclusions: 
 
LA diameter is a poor indicator of LA size, with a range of
error which is wide. In patients with MS in SR, LA volume is a better pre-
dictor of thromboembolic risk. We suggest using BSA-indexed LA volume to
guide anticoagulation decisions and with a threshold of 60 ml/m
 
2
 
 which has a
good sensitivity albeit with a low specificity.
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Impact of coronary artery disease on management of patients refer-
red for transcatheter aortic valve implantation
 
Mathieu Gautier, Marion Pépin, Dominique Himbert, Grégory Ducrocq,
Bernard Iung, David Attias, Caroline Cueff De Monchy, Jean-Michel
Juliard, Patrick Nataf, Alec Vahanian
CHU Bichat, Cardiologie, Paris, France
Purpose:
 
 To describe the impact of coronary artery disease (CAD) on
management of high-risk patients with aortic stenosis referred for transcatheter
aortic valve implantation (TAVI). 
Methods: Of 240 patients referred for TAVI, 145 (60%) effectively underwent
TAVI, while 31 (13%) were re oriented towards conventional surgery and 64
(27%) were conservatively managed. We compared the 147 patients (61%)
with CAD with the 93 (39%) with no CAD. 
 
Results:
 
 Patients with CAD presented with one or several of the following:
previous myocardial infarction in 54 (37%), coronary artery bypass grafting
(CABG) in 63 (43%), percutaneous coronary intervention (PCI) in 49 (33%).
CAD was diagnosed during the screening for TAVI in 46 (31%). CAD led to
re orient 5 patients (2%) towards conventional surgery for combined aortic
valve replacement and CABG, and to perform PCI before TAVI in 9 (6%) or
during the procedure in 2 (1%). No patient was denied any intervention
because of CAD. The comparison between patients with and without CAD is
detailed in the Table. 
 
Conclusions: 
 
In high-risk patients referred for TAVI, CAD is frequent and
associated with worse baseline characteristics, but has a limited impact on
indications for TAVI. It seldom requires associated revascularisation and has
no impact on mid-term results of TAVI.   
 Overall (n=240) CAD (n=147) no CAD (n=93) p
Age (years) 81±8 81±9 83±7 0.07
Female gender 111 (46%) 47 (32%) 64 (69%) <0.0001
Carotid artery disease 58 (24%) 50 (34%) 8 (9%) <0.0001
Renal failure 89 (37%) 63 (43%) 26 (28%) 0.03
 2 comorbidities 151 (63%) 104 (71%) 47 (50%) 0.002
EuroSCORE (%) 28±16 31±17 24±12 0.001
TAVI performed 145 (60%) 83 (56%) 62 (67%) 0.11
TAVI procedural success 141 (97%) 81 (98%) 60 (97%) 0.76
post-TAVI troponin (mcg/L) 4.5±0.6 5.2±0.7 3.5±0.9 0.07
30-day post TAVI survival (%) 88 91 85 0.25
1-year post TAVI survival (%) 74±4 76±5 71±7 0.36
NYHA I/II last follow-up (%) 85 85 85 0.73
